NeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report issued on Thursday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Trading Up 1.7 %

NASDAQ NURO opened at $3.57 on Thursday. The business’s 50-day moving average price is $3.74 and its two-hundred day moving average price is $3.82. NeuroMetrix has a 12 month low of $2.70 and a 12 month high of $11.82. The firm has a market capitalization of $7.10 million, a PE ratio of -0.57 and a beta of 2.26.

NeuroMetrix (NASDAQ:NURO) last released its quarterly earnings results on Thursday, February 22nd. The medical device company reported ($1.43) EPS for the quarter. NeuroMetrix had a negative net margin of 110.64% and a negative return on equity of 31.31%. The company had revenue of $1.32 million during the quarter.

Institutional Investors Weigh In On NeuroMetrix

Institutional investors and hedge funds have recently made changes to their positions in the business. Virtu Financial LLC bought a new stake in shares of NeuroMetrix during the 4th quarter valued at about $43,000. Cerity Partners LLC bought a new stake in shares of NeuroMetrix during the 4th quarter valued at about $108,000. Millennium Management LLC boosted its position in shares of NeuroMetrix by 102.3% during the 4th quarter. Millennium Management LLC now owns 20,530 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 10,384 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of NeuroMetrix by 30.7% during the 4th quarter. Renaissance Technologies LLC now owns 36,854 shares of the medical device company’s stock valued at $55,000 after purchasing an additional 8,654 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of NeuroMetrix by 11.1% during the 3rd quarter. Vanguard Group Inc. now owns 350,029 shares of the medical device company’s stock valued at $977,000 after purchasing an additional 34,892 shares in the last quarter. Institutional investors own 19.40% of the company’s stock.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies.